Update shared on10 Aug 2025
Fair value Decreased 7.27%Despite an improved revenue growth outlook, a significantly higher discount rate has outweighed this positive, leading to a reduced fair value estimate for DENTSPLY SIRONA, with the consensus analyst price target declining from $18.18 to $17.14.
What's in the News
- Reaffirmed 2025 earnings guidance, expecting net sales of $3.60–$3.70 billion (down 4.0% to 2.0% constant currency), reflecting current tariffs and trade policy.
- Issued Q2 2025 guidance, anticipating net sales of approximately $935 million.
- Daniel Scavilla appointed CEO effective August 1, 2025, succeeding Simon Campion; Scavilla brings experience from Globus Medical and Johnson & Johnson.
- Matthew E. Garth appointed CFO effective May 30, 2025, bringing nearly 30 years' financial leadership from Scotts Miracle-Gro, Minerals Technologies, and Alcoa.
Valuation Changes
Summary of Valuation Changes for DENTSPLY SIRONA
- The Consensus Analyst Price Target has fallen from $18.18 to $17.14.
- The Consensus Revenue Growth forecasts for DENTSPLY SIRONA has significantly risen from 1.6% per annum to 2.5% per annum.
- The Discount Rate for DENTSPLY SIRONA has significantly risen from 8.71% to 9.65%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.